Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Pfizer To Present Multiple Myeloma Related Phase 1 Results Evaluating PD0332991 At ASH

Home/Pfizer To Present Multiple Myeloma Related Phase 1 Results Evaluating PD0332991 At ASH

Pfizer To Present Multiple Myeloma Related Phase 1 Results Evaluating PD0332991 At ASH

While I was researching my pre-ASH article on our Help With Cancer.org site this morning (that is where I post non-myeloma related cancer news from large oncology conferences like ASH and ASCO), I found this interesting tidbit burried deep in one of Pfizer’s press releases:

A Phase 1 trial evaluating PD 0332991 in combination with bortezomib or dexamethasone in relapsed or refractory multiple myeloma. PD 0332991 is a selective inhibitor of cyclin-dependent kinase (CDK) 4/6.(12)

Pfizer’s emphasis is leukemia and lymphoma.  They are also doing some solid tumor work.  So I was a bit surprised to discover they will be presenting some Phase 1 multiple myeloma related results.  Since Millennium makes bortesomib (Velcade), I will speak with some of my contacts there and see what I can find out.

Feel good and keep smiling!  Pat